承基

Chengji Biopharma is a biotechnology company specializing in the development of circular RNA (circRNA) therapeutics and vaccines. Founded in 2021 and based in Shanghai, the company leverages its proprietary platform to design and manufacture stable, long-lasting RNA molecules that overcome the limitations of traditional linear mRNA, such as short half-life and high immunogenicity. Chengji's pipeline includes vaccines for infectious diseases like COVID-19 and influenza, as well as therapeutic candidates for oncology and rare genetic disorders. By optimizing RNA circularization and translation efficiency, the company aims to provide more effective and durable treatments. Backed by prominent investors such as Legend Capital and Qiming Venture Partners, Chengji Biopharma is a leading player in the emerging field of circular RNA medicine in China.